九洲药业(603456) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,373,675,379.24, representing a year-on-year increase of 60.46%[4] - The net profit attributable to shareholders for Q1 2022 was ¥207,810,018.06, reflecting a significant increase of 120.13% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥195,536,741.57, up by 102.28% year-on-year[4] - Basic earnings per share for Q1 2022 were ¥0.25, an increase of 127.27% year-on-year[4] - Total operating revenue for Q1 2022 reached RMB 1,373,675,379.24, a significant increase of 60.4% compared to RMB 856,095,409.40 in Q1 2021[17] - Net profit for Q1 2022 was RMB 207,376,991.20, representing a 119.5% increase from RMB 94,680,696.08 in Q1 2021[18] - Total comprehensive income for Q1 2022 amounted to RMB 206,478,271.34, compared to RMB 93,295,524.19 in Q1 2021[19] Cash Flow - The net cash flow from operating activities reached ¥382,358,482.10, showing a dramatic increase of 3,701.30% compared to the previous year[4] - Cash flow from operating activities for Q1 2022 was RMB 382,358,482.10, a substantial increase from RMB 10,058,629.63 in Q1 2021[20] - The company reported a significant increase in cash received from sales and services, totaling RMB 1,393,123,966.88 in Q1 2022, compared to RMB 704,946,040.92 in Q1 2021[20] - The net increase in cash and cash equivalents was $420,117,429.98, compared to $407,343,149.54 in the prior period[22] - The ending balance of cash and cash equivalents reached $1,146,862,958.00, up from $662,168,970.28[22] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥7,545,719,098.08, a 7.18% increase from the end of the previous year[5] - The equity attributable to shareholders at the end of Q1 2022 was ¥4,791,856,911.81, up by 4.69% from the previous year[5] - The company's current assets totaled RMB 4,191,022,995.91, up from RMB 3,771,883,813.73 at the end of 2021, indicating an increase of about 11.1%[14] - The company's total liabilities increased to RMB 2,745,405,077.88 from RMB 2,463,293,930.93, which is an increase of approximately 11.4%[15] - The equity attributable to shareholders of the parent company was RMB 4,791,856,911.81, up from RMB 4,577,129,753.17, representing an increase of about 4.7%[16] Research and Development - The company attributed its performance growth primarily to the strong increase in CDMO business, driven by expanded customer base and product pipeline[6] - The company continues to adhere to the highest international quality regulatory standards, focusing on accelerating the R&D of innovative drugs[5] - Research and development expenses increased to RMB 64,192,677.61 in Q1 2022, up 81.6% from RMB 35,357,842.45 in Q1 2021[17] - The company plans to continue investing in R&D to drive future growth and innovation[18] Investment and Financing Activities - Investment activities cash outflow totaled $195,678,925.38, an increase from $126,399,102.80 in the previous period[22] - Net cash flow from investment activities was -$163,723,600.90, compared to -$111,308,516.80 previously[22] - Cash inflow from financing activities amounted to $683,816,779.30, down from $1,388,999,985.39[22] - Net cash flow from financing activities was $202,303,178.95, a decrease from $508,118,012.53[22] - The company reported a cash outflow of $474,000,000.00 for debt repayment, down from $871,592,500.00[22] Other Financial Metrics - The weighted average return on equity increased by 1.95 percentage points to 4.44%[4] - Other comprehensive income after tax for Q1 2022 was RMB -898,719.86, an improvement from RMB -1,385,171.89 in Q1 2021[19] - The company completed the deregistration of its joint venture FJ Pharma, LLC in January 2022, which was approved by the board in April 2020[12] - The impact of exchange rate changes on cash and cash equivalents was -$820,630.17, contrasting with a positive impact of $475,024.18 in the previous period[22] - The company did not apply the new accounting standards for the first quarter of 2022[23]